Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Parkinson Disease Clinical Trial

— TEMPO-3  

Official title:

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04542499
• Other study ID #: CVL-751-PD-003
• Secondary ID: 2019-002951-40
• Status: Completed
• Phase: Phase 3
• Start date: October 27, 2020
• Est. completion date: February 15, 2024

Study information

• Verified date: April 2024
• Source: Cerevel Therapeutics, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 507
• Est. completion date: February 15, 2024
• Est. primary completion date: January 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Key Inclusion Criteria:

• Male and female participants aged 40 to 80 years, inclusive, at the time of signing the informed consent form (ICF).
• Sexually active men or women of childbearing potential must agree to use acceptable (at minimum) or highly effective birth control, or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment.
• Participants who are capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
• Participants with a diagnosis of PD that is consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria, with bradykinesia and motor asymmetry.
• Participants with modified Hoehn and Yahr stage 2, 2.5, or 3 in the "on" state.
• Participants with a good response to levodopa (L-Dopa) in the judgment of the investigator.
• Participants who return a completed self-reported home diary for motor function status (Hauser diary) during the screening period (after diary training and concordance testing has occurred), with recordings for 2 consecutive days (ie, 2 consecutive 24-hour periods) showing at least 2 and half hours of "off" time on each of the 2 days.
• Participants who are on a stable dose of L-Dopa for at least 4 weeks prior to screening and are taking a minimum total daily dose of 400 milligram (mg) divided in at least 4 doses per day of standard carbidopa/levodopa or divided in at least 3 doses per day of extended-release carbidopa/levodopa capsules. The carbidopa/levodopa dose and frequency must be maintained for the duration of the trial.
• Prior and concurrent use of catechol-O-methyl transferase (COMT) inhibitors, monoamine oxidase B (MAO-B) inhibitors, amantadine, istradefylline or anticholinergic drugs are permitted if the use was initiated greater than (>) 90 days before the baseline visit and the dosage will remain stable for the duration of the trial (ie, no change in the COMT, MAO-B inhibitor, amantadine, istradefylline or anticholinergic dose is permitted during the trial).

Key Exclusion Criteria:

• Participants with a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supranuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug-induced or poststroke parkinsonism).
• Participants with a history of nonresponse or insufficient response to L-Dopa at therapeutic dosages.
• Participants with a history or current diagnosis of a clinically significant impulse control disorder (Disruptive, Impulse Control, and Conduct Disorder per DSM-5).
• Participants with the presence of or history of brain tumor, hospitalization for severe head trauma, epilepsy (as defined by the International League Against Epilepsy), or seizures.
• Participants with a history of psychosis or hallucinations within the previous 12 months.
• Participants who answer "yes" on the Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR Participants who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide.
• Participants with substance abuse or dependence disorder, including alcohol, benzodiazepines, and opioids, but excluding nicotine, within the past 6 months (180 days).
• Participants with dementia or cognitive impairment that, in the judgement of the investigator, would exclude the participant from understanding the ICF or participating in the trial.
• Participants with any condition that could possibly affect drug absorption, including bowel resections, bariatric weight loss surgery, or gastrectomy (this does not include gastric banding).
• Participants who have a positive result for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV) antibodies at screening.
• Participants with a history of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias that are not controlled with medical and/or surgical intervention; second- or third-degree atrioventricular block; sick sinus syndrome; severe or unstable angina; or congestive heart failure within the last 12 months. A recent (less than or equal to [<=12] months) history of myocardial infarction with secondary arrhythmias is exclusionary regardless of the therapeutic control.
• Participants with a history of neuroleptic malignant syndrome.
• Participants who are currently receiving moderate or strong CYP3A4 inducers or CYP3A4 inhibitors (except for topical administration).
• Participants with a positive urine drug screen for illicit drugs are excluded and may not be retested or rescreened. Participants with a positive urine drug screen resulting from use of marijuana (any tetrahydrocannabinol-containing product), prescription, or over-the-counter medications or products that, in the investigator's documented opinion, do not signal a clinical condition that would impact the safety of the participant or interpretation of the trial results may continue evaluation for the trial following consultation and approval by the medical monitor
• Participants with a Montreal Cognitive Assessment (MoCA) score <26.
• Participants with clinically significant orthostatic hypotension (eg, syncope).
• Participants with a 12-lead ECG demonstrating a QTcF interval >450 msec.
• Participants with moderate or severe renal impairment (creatinine clearance as estimated by Cockcroft-Gault formula <30 mL/min or on dialysis).
• Participants with any of the following abnormalities in clinical laboratory tests at the Screening Visit, as assessed by the central laboratory and confirmed by a single

repeat measurement, if deemed necessary:

• Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) >=3 × Upper Limit Normal (ULN).
• Total bilirubin >=1.5 × ULN. Participants with a history of Gilbert's syndrome may be eligible provided they have a value <ULN for direct bilirubin
• Participants with other abnormal laboratory test results, vital sign results, or ECG findings unless, in the judgment of the investigator, the findings are not medically significant and would not impact the safety of the participants or the interpretation of the trial results.

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Drug:
• Tavapadon
Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
• Placebo
Participants will receive placebo matching to tavapadon QD orally for 27 weeks.

Locations

Country	Name	City	State
Australia	Erina, New South Wales	Erina	New South Wales
Australia	Kogarah, New South Wales	Kogarah	New South Wales
Australia	Parkville, Victoria	Parkville	Victoria
Australia	Woolloongabba, Queensland	Woolloongabba	Queensland
Bulgaria	Pleven	Pleven
Bulgaria	Sofia	Sofia
Bulgaria	Sofia	Sofia
Bulgaria	Sofia	Sofia
Bulgaria	Sofia	Sofia
Bulgaria	Sofia	Sofia
Czechia	Chocen	Chocen	Chocen
Czechia	Prague	Prague
Czechia	Prague,	Prague
Czechia	Prague,	Prague
Czechia	Rychnov nad Knežnou	Rychnov Nad Knežnou
France	Creteil,	Créteil	Creteil
France	Nantes CEDEX 1	Nantes
France	Nîmes cedex	Nîmes
France	Toulouse Cedex	Toulouse
Germany	Bad Homburg	Bad Homburg
Germany	Berlin	Berlin
Germany	Bochum	Bochum
Germany	Brandenburg,	Brandenburg
Germany	Gera	Gera
Germany	Haag in Oberbayern	Haag In Oberbayern
Germany	Muenchen	Muenchen
Germany	Klinikum rechts der Isar der TU München	München
Germany	Muenster	Münster	Muenster
Israel	Tel Aviv	Tel Aviv
Italy	Ancona	Ancona
Italy	Cassino	Cassino
Italy	Milano	Milano
Italy	Padova	Padova
Italy	Pisa	Pisa
Italy	Rome	Rome
Italy	Rome	Rome
Italy	Rome	Rome
Italy	Rozzano Milano	Rozzano
Poland	Bydgoszcz	Bydgoszcz
Poland	Katowice	Katowice
Poland	Krakow	Krakow
Poland	Krakow	Krakow
Poland	Krakow	Krakow
Poland	Kraków	Kraków
Poland	Lublin	Lublin
Poland	Siemianowice Slaskie	Siemianowice Slaskie	Siemianowice Slaskie
Poland	Warsaw,	Warsaw
Serbia	Kragujevac	Kragujevac
Spain	Barcelona	Barcelona
Spain	Barcelona	Barcelona
Spain	Elche	Elche	Alicante
Spain	Madrid	Madrid
Spain	Madrid	Madrid
Spain	Terrassa	Terrassa
Ukraine	Lviv	Lviv
Ukraine	Vinnitsa	Vinnitsa
United States	Augusta, Georgia	Augusta	Georgia
United States	Boca Raton, Florida	Boca Raton	Florida
United States	Boston, Massachusettes	Boston	Massachusetts
United States	Chicago, Illinois	Chicago	Illinois
United States	Cleveland, Ohio	Cleveland	Ohio
United States	Columbus, Ohio	Columbus	Ohio
United States	Coral Springs, Florida	Coral Springs	Florida
United States	Cypress, Texas	Cypress	Texas
United States	Farmington Hills, Michigan	Farmington Hills	Michigan
United States	Adventura, Florida	Florida City	Florida
United States	Frenso, California	Fresno	California
United States	Hallandale Beach, Florida	Hallandale Beach	Florida
United States	Houston,Texas	Houston	Texas
United States	Kirkland, Washington	Kirkland	Washington
United States	Las Vegas, Nevada	Las Vegas	Nevada
United States	Little Rock, Arkansas	Little Rock	Arkansas
United States	Los Angeles, California	Los Angeles	California
United States	Lubbock, Texas	Lubbock	Texas
United States	Maitland, Florida	Maitland	Florida
United States	Memphis, Tennessee	Memphis	Tennessee
United States	North Dartmouth, Massachusetts	North Dartmouth	Massachusetts
United States	Ocala, Florida	Ocala	Florida
United States	Port Charlotte, Florida	Port Charlotte	Florida
United States	Port Orange, Florida	Port Orange	Florida
United States	Richmond, Virginia	Richmond	Virginia
United States	Round Rock, Texas	Round Rock	Texas
United States	Scarborough, Maine	Scarborough	Maine
United States	Tampa, Florida	Tampa	Florida
United States	Toledo, Ohio	Toledo	Ohio
United States	Winter Park, Florida	Winter Park	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Cerevel Therapeutics, LLC

Countries where clinical trial is conducted

United States,  Australia,  Bulgaria,  Czechia,  France,  Germany,  Israel,  Italy,  Poland,  Serbia,  Spain,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)	The Hauser diary (Hauser et al, 2000) assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total "on" time without troublesome dyskinesia will be assessed and reported at endpoint.	27 Weeks
Secondary	Change From Baseline in Total Daily "Off" Time Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)	The Hauser diary (Hauser et al, 2000) assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total daily "Off" time will be assessed and reported at endpoint.	27 Weeks
Secondary	Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)	The Hauser diary (Hauser et al, 2000) assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total "on" time without troublesome dyskinesia will be assessed and reported at different time points.	Baseline, Weeks 2, 5, 8, 11, 14, 18, 22, 26, and 27
Secondary	Change From Baseline in Total Daily "Off" Time Without Troublesome Dyskinesia Based on the 2-Day Average of the Self-Completed Home Diary for Motor Function Status (Hauser Diary)	The Hauser diary (Hauser et al, 2000) assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep. The total daily "Off" time will be assessed and reported at different time points.	Baseline, Weeks 2, 5, 8, 11, 14, 18, 22, 26, and 27
Secondary	Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and III Individual Score	The MDS-UPDRS is a multidimensional scale that assesses the motor and non-motor impacts of PD across 4 parts. Part I, non-motor aspects of experiences of daily living, comprises 13 items, 6 of which are rated by the physician (Part IA) and 7 of which are rated by the participant (Part IB). Part II, motor aspects of experiences of daily living, comprises 13 items that are rated by the participant. Part III, motor examination, comprises 18 items that are assessed by the investigator (resulting in 33 scores by location and lateralization). Part IV, motor complications, comprises 6 item (3 items for dyskinesia and 3 items for fluctuation) and requires the physician to use historical and objective information to assess dyskinesia and motor fluctuations. Each item of all the parts will be rated on a scale from 0 to 4 on which 0 = normal, 1=slight, 2=mild, 3=moderate, and 4=severe. Change from baseline in MDS-UPDRS parts I, II and III Individual score will be assessed.	27 Weeks